CN107405315A - 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 - Google Patents

用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 Download PDF

Info

Publication number
CN107405315A
CN107405315A CN201680017379.4A CN201680017379A CN107405315A CN 107405315 A CN107405315 A CN 107405315A CN 201680017379 A CN201680017379 A CN 201680017379A CN 107405315 A CN107405315 A CN 107405315A
Authority
CN
China
Prior art keywords
disease
effective dose
treating
dnp
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680017379.4A
Other languages
English (en)
Chinese (zh)
Inventor
R.阿龙索
J.G.盖斯勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitochon Pharmaceuticals Inc
Original Assignee
Mitochon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitochon Pharmaceuticals Inc filed Critical Mitochon Pharmaceuticals Inc
Priority to CN202211548767.9A priority Critical patent/CN116617195A/zh
Publication of CN107405315A publication Critical patent/CN107405315A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201680017379.4A 2015-01-22 2016-01-21 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 Pending CN107405315A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211548767.9A CN116617195A (zh) 2015-01-22 2016-01-21 脑源性神经营养因子的诱导表达

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106365P 2015-01-22 2015-01-22
US62/106365 2015-01-22
PCT/US2016/014312 WO2016118741A1 (en) 2015-01-22 2016-01-21 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211548767.9A Division CN116617195A (zh) 2015-01-22 2016-01-21 脑源性神经营养因子的诱导表达

Publications (1)

Publication Number Publication Date
CN107405315A true CN107405315A (zh) 2017-11-28

Family

ID=55310938

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680017379.4A Pending CN107405315A (zh) 2015-01-22 2016-01-21 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达
CN202211548767.9A Pending CN116617195A (zh) 2015-01-22 2016-01-21 脑源性神经营养因子的诱导表达

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211548767.9A Pending CN116617195A (zh) 2015-01-22 2016-01-21 脑源性神经营养因子的诱导表达

Country Status (13)

Country Link
US (6) US9763896B2 (enExample)
EP (2) EP4306167B1 (enExample)
JP (3) JP6951976B2 (enExample)
KR (1) KR102690198B1 (enExample)
CN (2) CN107405315A (enExample)
AU (2) AU2016209255B2 (enExample)
BR (1) BR112017015721A2 (enExample)
CA (1) CA2974092A1 (enExample)
ES (1) ES2961334T3 (enExample)
HK (1) HK1247101A1 (enExample)
MX (2) MX392410B (enExample)
PT (1) PT3247340T (enExample)
WO (1) WO2016118741A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4306167B1 (en) * 2015-01-22 2025-12-24 Mitochon Pharmaceuticals, Inc. Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
WO2018129258A1 (en) 2017-01-06 2018-07-12 Gencia Corporation Novel phenyl derivatives
WO2018144551A2 (en) * 2017-01-31 2018-08-09 Manfredi Paolo L Compounds for treatment or prevention of disorders of the nervous system and symptoms and manifestations thereof, and for cyto-protection against diseases and aging of cells, and symptoms and manifestations thereof
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10675255B2 (en) 2017-06-23 2020-06-09 Enzo Bochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
KR20220044150A (ko) * 2020-09-29 2022-04-06 (주)세포바이오 Manf를 포함하는 신경정신질환의 예방 또는 치료용 조성물
WO2023205625A2 (en) * 2022-04-18 2023-10-26 Mitochon Pharmaceuticals, Inc. 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases
WO2025051360A1 (en) * 2023-09-06 2025-03-13 Instituto de Medicina Molecular João Lobo Antunes Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1764095A1 (en) * 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
WO2009008991A2 (en) * 2007-07-06 2009-01-15 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Dna-pkcs modulates energy regulation and brain function
WO2015031756A1 (en) * 2013-08-30 2015-03-05 Yale University Novel 2,4-dinitrophenol formulations and methods using same
EP4306167B1 (en) * 2015-01-22 2025-12-24 Mitochon Pharmaceuticals, Inc. Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

Also Published As

Publication number Publication date
JP6951976B2 (ja) 2021-10-20
EP4306167B1 (en) 2025-12-24
JP7440092B2 (ja) 2024-02-28
US11717497B2 (en) 2023-08-08
EP3247340B1 (en) 2023-08-02
MX392410B (es) 2025-03-11
US10220006B2 (en) 2019-03-05
KR102690198B1 (ko) 2024-07-30
EP3247340A1 (en) 2017-11-29
HK1247101A1 (zh) 2018-09-21
MX2017009402A (es) 2017-12-04
JP2022173519A (ja) 2022-11-18
MX2022005937A (es) 2022-06-29
US20210052513A1 (en) 2021-02-25
BR112017015721A2 (pt) 2018-04-10
PT3247340T (pt) 2023-10-31
US20170065536A1 (en) 2017-03-09
AU2021240120A1 (en) 2021-10-28
AU2016209255A1 (en) 2017-08-10
JP2018502898A (ja) 2018-02-01
US9763896B2 (en) 2017-09-19
US20190142765A1 (en) 2019-05-16
AU2016209255B2 (en) 2021-07-01
US20180125794A1 (en) 2018-05-10
JP2021080286A (ja) 2021-05-27
CN116617195A (zh) 2023-08-22
ES2961334T3 (es) 2024-03-11
WO2016118741A1 (en) 2016-07-28
US10864173B2 (en) 2020-12-15
EP4306167A3 (en) 2024-03-20
CA2974092A1 (en) 2016-07-28
EP4306167A2 (en) 2024-01-17
US9974755B2 (en) 2018-05-22
KR20170104597A (ko) 2017-09-15
US20240156750A1 (en) 2024-05-16
US20160213625A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
JP7440092B2 (ja) 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
AU2001242568B2 (en) Treatment of movement disorders
AU2001242568A1 (en) Treatment of movement disorders
US20250188461A1 (en) Methods of treating osmidrosis
Khan Off spells and dyskinesias: pharmacologic management of motor complications
WO2020198039A1 (en) Ketamine for treatment of sensory processing deficits
HK40106997A (en) Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
Sharma et al. Recovery of the injured neural system through gene delivery to surviving neurons in Parkinson’s disease
JP2004512360A (ja) ５−ヒドロキシトリプタミン１ａレセプター活性増強化合物を用いる運動症状の変動の治療
CA3076180C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
Chunder Pregabalin
Behrens et al. Non-oral drug delivery in Parkinson’s disease: a summary from the symposium at the 7th International Congress of Parkinson’s Disease and Movement Disorders
Reichmann et al. NEW DEVELOPMENTS FOR PARKINSON’S THERAPY WITH COMT INHIBITORS
Tankosic Parkinson's disease: new dopaminergic delivery but neuroprotection remains elusive

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1247101

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20171128

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1247101

Country of ref document: HK